OPE™ IPL (Optimal Power Energy)
Optimal Power Energy, written as OPE™ IPL, is Espansione's patented intense pulsed light technology, engineered to be among the safest and most ergonomic IPL systems available. Where LM™ LLLT (PBM) is the primary therapeutic modality across the platform, OPE™ IPL is positioned as an adjunct, most useful for the lid-driven, inflammatory component of recalcitrant or severe meibomian gland dysfunction.
How IPL differs from LLLT
Intense pulsed light is polychromatic, meaning it delivers a broad band of wavelengths in calibrated thermal pulses, rather than the single, non-thermal wavelength used in photobiomodulation. Its strengths sit at the eyelid and its margin: warming and supporting meibomian gland function, and addressing the inflammatory and vascular component that often underlies stubborn meibomian gland dysfunction. For a direct comparison, see IPL vs LLLT.
Engineered to be used without gel
Conventional IPL requires a coupling gel and careful protection because of how it delivers energy to the skin. OPE™ IPL is designed differently: its intensity self-modulates toward a skin-safe optimum, which allows it to be used without gel. This makes treatment faster and more ergonomic for the clinician and more comfortable for the patient, while keeping energy delivery within a controlled, skin-safe range.
Safety considerations
Because IPL delivers light to the skin, it carries considerations that LLLT does not. Photosensitising medications and a personal history of photosensitivity reactions matter, and screening before treatment is part of good practice. The gel-free, self-modulating design is intended to widen applicability and ease delivery, but it does not remove the need for that screening. The TFOS DEWS III report notes that the contraindication and precaution literature for both IPL and LLLT is not exhaustively defined, so clinical judgement and review of the device Instructions for Use remain the appropriate framework. See safety by design.
Where the evidence supports it
OPE™ IPL is most strongly supported in combination with LM™ LLLT. Combined therapy on eye-light® outperformed an IPL-only comparator at eighteen-month follow-up in MGD (Leite et al., 2025) and bettered IPL-only competitor devices on lipid layer thickness and symptoms (Castro et al., 2023). In a direct comparison of the two modalities alone, LM™ LLLT outperformed OPE™ IPL on symptoms and tear meniscus height at two weeks (Giannaccare et al., 2022, Cornea), which is why IPL is framed as an adjunct rather than a default first move. See combined therapy.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.